Determinants Affecting the Clinical Implementation of a Molecularly Informed Molecular Tumor Board Recommendation: Experience from a Tertiary Cancer CenterLars Tögel, Silvia Spoerl, Juliane Hoyer et al.|Cancers|2023Cited by 14
Limited association between <scp>HRR</scp> gene alterations and <scp>HRD</scp> in molecular tumor board cancer samples: Who should be tested for <scp>HRD</scp>?Christoph Schubart, Evgeny A. Moskalev, Lars Tögel et al.|International Journal of Cancer|2025Cited by 1